← Back to Search

Afferent Block for Heart Failure

N/A
Recruiting
Led By Markus Amann, PhD
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Heart failure with preserved ejection fraction
Be older than 18 years old
Must not have
Heart failure with reduced ejection fraction
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial will help researchers understand why patients with heart failure and preserved ejection fraction (HFpEF) are intolerant to exercise, and if regular physical activity can help improve this.

Who is the study for?
This trial is for Veterans with a type of heart failure where the heart muscle pumps out a normal amount of blood (HFpEF). It's not for those whose hearts can't pump enough blood (reduced ejection fraction). Participants will explore how exercise affects their condition.
What is being tested?
The study tests whether blocking certain nerves in limb muscles can improve exercise tolerance and fatigue resistance in patients. The focus is on regular physical activity as an alternative treatment to enhance quality of life.
What are the potential side effects?
While specific side effects are not detailed, interventions involving nerve blocks may include discomfort at the injection site, potential nerve damage, or temporary muscle weakness.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My heart pumps well but is stiff.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My heart pumps less blood than normal.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
femoral blood flow

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Effect of cardiac rehabExperimental Treatment1 Intervention
Evaluate effect of chronic exercise on influence of muscle afferents on limb blood flow
Group II: Afferent effect on hemodynamicsExperimental Treatment1 Intervention
Evaluate impact of group III/IV muscle afferents on femoral blood flow
Group III: Afferent effect on fatigueExperimental Treatment1 Intervention
Evaluate impact of group III/IV muscle afferents on exercise-induced changes in quadriceps twitch force

Find a Location

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,668 Previous Clinical Trials
3,765,816 Total Patients Enrolled
39 Trials studying Heart Failure
63,265 Patients Enrolled for Heart Failure
Markus Amann, PhDPrincipal InvestigatorVA Salt Lake City Health Care System, Salt Lake City, UT
2 Previous Clinical Trials
176 Total Patients Enrolled
2 Trials studying Heart Failure
176 Patients Enrolled for Heart Failure

Media Library

Afferent block Clinical Trial Eligibility Overview. Trial Name: NCT04506606 — N/A
Heart Failure Research Study Groups: Afferent effect on hemodynamics, Afferent effect on fatigue, Effect of cardiac rehab
Heart Failure Clinical Trial 2023: Afferent block Highlights & Side Effects. Trial Name: NCT04506606 — N/A
Afferent block 2023 Treatment Timeline for Medical Study. Trial Name: NCT04506606 — N/A
~10 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top